Sweden · Delayed Price · Currency is SEK Immunovia AB Earnings Call Transcripts
Fiscal Year 2025
-
PancreaSure launched in Q4 2025 with early adoption at 12 centers and strong clinical validation. Revenue remains modest, but a SEK 69.8 million rights issue extends cash runway through Q3 2026. Medicare coverage submission is planned for mid-2026, with significant revenue expected in 2027.
-
Transitioned to commercial stage with PancreaSure, achieving early adoption at top cancer centers and securing a Medicare reimbursement rate. Q3 saw reduced losses and a strengthened cash position, with significant revenue growth expected as reimbursement milestones are met.
-
PancreaSure, a new early detection test for pancreatic cancer, launches next week with strong scientific endorsement and initial adoption by seven top U.S. centers. Q2 saw reduced expenses, a SEK 100 million rights issue, and progress toward reimbursement and commercialization.
-
Transitioning to commercialization, the PancreaSure test is set for a September 2025 launch, showing strong clinical performance and doubling its addressable market. Cash reserves are expected to last through Q3, with ongoing efforts to secure partnerships and reimbursement.
-
A clinical validation study in high-risk individuals showed a next-generation blood test detects early-stage pancreatic cancer with 77% sensitivity and 88% specificity, outperforming standard imaging and CA 19-9. Combined with prior data, results support reimbursement, regulatory approval, and a targeted US launch in Q3 2025.
Fiscal Year 2024
-
Clinical validation of the next-generation pancreatic cancer test showed high sensitivity and specificity, outperforming current standards and enabling commercialization in Q3 2025. Financials remain stable with strong investor support, and additional studies and strategic partnerships are underway.
-
A large clinical validation study showed a next-generation blood test for early pancreatic cancer detection achieved 78% sensitivity and 94% specificity in high-risk individuals, outperforming current biomarkers and imaging standards. Performance was even higher in recent samples, and the test is set for U.S. launch next year.
-
Q3 saw major progress in next-gen test validation, with strong sensitivity and specificity results. Financial discipline led to reduced OpEx and cash burn, while a successful rights issue bolstered liquidity. U.S. launch and strategic partnerships are planned for 2025, with clinical validation data due in December.
-
Delivered a next-generation pancreatic cancer test with 98% specificity and 85% sensitivity, reduced OpEx and cash burn, and secured inclusion in a major NIH-funded study. Rights issue underway to fund validation and commercialization, with cash runway through 2024.